Ikarian Capital’s Mereo BioPharma MREO Stock Holding History

Ikarian Capital’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-591,676	Closed	-$191K	–	161
2023 Q3	$191K	Sell	591,676 -300,000	-34%	-$398K	0.02%	122
2023 Q2	$300K	Buy	+891,676	New	+$1.03M	0.05%	106
2022 Q3	–	Sell	-615,856	Closed	-$199K	–	144
2022 Q2	$199K	Sell	615,856 -300,000	-33%	-$232K	0.04%	121
2022 Q1	$318K	Buy	915,856 +62,176	+7%	+$80.4K	0.04%	154
2021 Q4	$307K	Sell	853,680 -50,000	-6%	-$100K	0.05%	149
2021 Q3	$322K	Sell	903,680 -40,628	-4%	-$108K	0.02%	196
2021 Q2	$346K	Sell	944,308 -202,000	-18%	-$678K	0.03%	196
2021 Q1	$419K	Hold	1,146,308	–	–	0.01%	260
2020 Q4	$416K	Sell	1,146,308 -50,000	-4%	-$125K	0.02%	196
2020 Q3	$688K	Buy	+1,196,308	New	+$3.5M	0.05%	136

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ikarian Capital's MREO Position: Q4 2023 in Review

Ikarian Capital sold out of Mereo BioPharma (MREO) in Q4 2023, closing a stake of 591,676 shares — an estimated $191K sold.

Ikarian Capital first reported a position in MREO in Q3 2020 and held it in 10 quarters. The position peaked at $688K in Q3 2020. 64 funds tracked by Wall St. Rank hold MREO as of Q4 2023.

Ikarian Capital reported no remaining Mereo BioPharma position as of Q4 2023 after selling out during the quarter.
Ikarian Capital sold 591,676 Mereo BioPharma shares in Q4 2023, an estimated $191K.
Ikarian Capital first reported a position in Mereo BioPharma in Q3 2020 and held it in 10 quarters.
Ikarian Capital's Mereo BioPharma position peaked at $688K in Q3 2020.
64 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2023.

Based on Ikarian Capital's 13F filing for Q4 2023, filed 14 Feb 2024.